Clinical Trial

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

Study acronym: HERCard
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and/or adjuvant trastuzumab-based therapies.
Trial Details
NCT Number NCT06762977
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators: Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Ospedale Di Summa-Perrino
Conditions Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2
Enrollment 180 participants
Start Date 2024-11-13
Primary Completion 2025-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-01-08